Filing summary
Entity discrepancy: The provided metadata names Tvardi Therapeutics, Inc., but the filing is Cara Therapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2015. The figures and disclosures below are for Cara Therapeutics.
Business context and reporting period
Cara was a clinical-stage biopharmaceutical company developing CR845-based candidates for pain and pruritus. It had no products available for sale; reported revenue was primarily collaboration revenue. Financial statements are unaudited and cover the three months ended March 31, 2015, compared with the same period in 2014.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 or prior balance |
|---|---|---|
| Total revenue | $489,000 | $178,000 |
| Research and development expense | $3.385 million | $2.201 million |
| General and administrative expense | $1.822 million | $1.398 million |
| Operating loss | $4.718 million | $3.421 million |
| Net loss | $4.689 million | $3.383 million |
| Basic and diluted loss per share | $0.21 | $0.22 |
| Operating cash used | $5.241 million | $3.091 million |
| Cash and cash equivalents, March 31 | $47.422 million | $52.663 million at December 31, 2014 |
| Total assets, March 31 | $51.654 million | $55.934 million at December 31, 2014 |
| Current liabilities, March 31 | $3.427 million | $3.398 million at December 31, 2014 |
Revenue consisted of $489,000 of collaboration revenue recognized from deferred Maruishi license-related payments; there was no clinical compound revenue in Q1 2015. The company reported no product-sales revenue. Gross margin is not presented as a meaningful metric in the filing. No debt is listed on the March 31 balance sheet; operating lease commitments totaled $2.318 million.
Material changes versus the prior comparable period
- Revenue rose 174%, but remained small relative to operating expenses.
- R&D expense increased 54%, principally reflecting development activity in the IV CR845 uremic-pruritus Phase 2 trial, increased personnel costs, and stock-based compensation.
- G&A expense increased 30%, including higher payroll, recruiting, and directors’ and officers’ insurance costs.
- Net loss widened by about $1.3 million. Loss per share was lower at $0.21 versus $0.22, with weighted-average shares increasing to 22.8 million from 15.7 million.
- Operating cash use increased by about $2.2 million. Cash and cash equivalents declined $5.241 million during the quarter; Q1 2014 cash had increased substantially because of IPO proceeds.
Outlook, commentary, and risks
- Management expected March 31 cash to fund operations for at least 15 months, excluding possible collaboration milestones. The filing also says cash was expected to be sufficient beyond one year. Management cautioned that trial timing and costs could cause cash to run out sooner than expected.
- The company expected significant future expenses and losses, including from planned IV CR845 Phase 3 trials, Oral CR845 development, regulatory work, and potential commercialization preparation. Additional financing would be required to meet all development objectives.
- Following an April 2015 FDA End-of-Phase 2 meeting, Cara planned an adaptive pivotal IV CR845 trial in abdominal laparoscopic surgery, subject to FDA protocol review, with initiation anticipated in Q3 2015 and completion expected in 2016. Two further Phase 3 trials were planned for the first half of 2016.
- Oral CR845 Phase 2 osteoarthritis trial initiation was anticipated in Q3 2015, with top-line data expected by year-end 2015. IV CR845 uremic-pruritus efficacy results were expected in Q2 2015.
- A shelf registration statement filed in March 2015 could permit offerings of up to $150 million in securities when effective; the filing does not establish that the registration was effective or that an offering occurred.
- Key risks include clinical and regulatory uncertainty, funding availability and potential dilution, manufacturing and commercialization execution, competition, intellectual-property protection, and dependence on collaborators and third parties. The company reported no material legal proceedings and no new or materially changed risk factors for the quarter.
Important facts for investors to verify
- Confirm the issuer: this is a Cara Therapeutics filing, not a Tvardi Therapeutics filing.
- Check subsequent FDA feedback, trial starts, enrollment, and results against the development timelines stated in 2015.
- Track cash burn and financing needs against management’s 15-month runway estimate, and verify whether the shelf registration became effective or was used.
- Assess the terms, timing, and likelihood of Maruishi and CKD milestones and royalties; future payments were uncertain and conditional on development or commercialization.
- Review the company’s later filings for changes in clinical strategy, financial position, risk disclosures, or accounting estimates.